There are currently 48 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Autism participants are Texas, California, New York and Tennessee.
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Recruiting
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors Identify the maximum tolerated dose (MTD)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut +5 locations
Conditions: Solid Tumors
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Recruiting
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Sharp Memorial Hospital, San Diego, California +32 locations
Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Recruiting
This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study. The purpose of this study is to find the highest dose of BI 770371 that people with advanced cancer can tolerate when taken alone or together with a medicine called ezabenlimab. BI 770371 and ezabenlimab are antibodies that may help the immune system fight cancer (checkpoint inhibitors). In this study, BI 7703... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Florida Cancer Specialists, Sarasota, Florida +4 locations
Conditions: Solid Tumors
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
Recruiting
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Sarah Cannon Research Institute, LLC, Nashville, Tennessee +3 locations
Conditions: Solid Tumors
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Recruiting
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: University of Arizona, Tucson, Arizona +9 locations
Conditions: Solid Tumors
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Recruiting
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/10/2024
Locations: City of Hope National Medical Center, Duarte, California +109 locations
Conditions: Solid Tumors
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
All
Ages:
All
Trial Updated:
04/10/2024
Locations: Southern Cancer Center, Daphne, Alabama +166 locations
Conditions: Solid Tumors
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +30 locations
Conditions: Solid Tumors
Screening Study for Participants With Malignant Tumors
Recruiting
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +123 locations
Conditions: Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Mayo Clinic Hospital, Phoenix, Arizona +17 locations
Conditions: Solid Tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: University of Arizona Cancer Center ( Site 0018), Tucson, Arizona +531 locations
Conditions: Solid Tumors, Hematologic Malignancies
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Recruiting
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut +40 locations
Conditions: Liposarcoma, CRC, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung, Solid Tumors